The suppression of EGFR-dependent signaling in nonepithelial cells in Tspan6-positive CRC and attenuation of ensued paracrine signaling acting on epithelial cells may explain why responses to Cetuximab-based therapy was independent of the Ras mutation status in this group of CRC patients. This evidence concerns the gene EGFR and colorectal carcinoma.